H.C. Wainwright Sticks to Their Buy Rating for Stemline Therapeutics Inc (STML)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Stemline Therapeutics Inc (STMLResearch Report), with a price target of $35. The company’s shares closed on Friday at $14.86.

Selvaraju observed:

“As we roll forward the DCF analysis, our estimated market value of the firm has increased to $1.60B vs. the previous $1.53B, which includes the asset value for 15% discount rate and 2% terminal growth rate. The probability of approval ascribed to SL-701 is 45%. Assuming roughly 45.1M shares outstanding as of mid-2020, this leads to a 12-month price target of approximately $35 per share.”

According to TipRanks.com, Selvaraju ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -8.4% and a 28.7% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.

Stemline Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $29.33, a 97.4% upside from current levels. In a report issued on August 2, Wedbush also upgraded the stock to Buy with a $20 price target.

See today’s analyst top recommended stocks >>

Based on Stemline Therapeutics Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.84 million. In comparison, last year the company had a GAAP net loss of $18.93 million.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701.